Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation

Key Points

• Semaglutide administration significantly decreases markers of cortical neuroinflammation, supporting its neuroprotective potential.
• The engineered exosomal delivery system enhances the activation of the SIRT1–FOXO3a–miR-124 signaling pathway, indicating a novel therapeutic mechanism.
• Observational analysis of signaling pathways in cultured neuronal models demonstrates the efficacy of semaglutide in reducing inflammation-related damage.
• These findings highlight the need for further research on exosomal therapies, as they may offer exciting new avenues in neuroinflammation treatment.